clinical trial · NCT05777993
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Pyruvate Kinase DeficiencyAnemia, HemolyticSickle Cell DiseaseThalassemiaMitapivat
brief summary
The primary objective of the study is to provide continued access to participants who are deriving clinical benefit from ongoing mitapivat treatment in an Agios-sponsored mitapivat study, in the opinion of the Investigator.
started
Jul 6, 2023
primary completion
Aug 1, 2029
completion
Aug 1, 2031
last updated
Oct 28, 2026
detailed description
Participants will continue the mitapivat dose regimen that they were receiving at the final visit of their antecedent study.
official title
A Rollover Study to Provide Continued Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol